BioTuesdays

Tag - Stifel

IntriCon Logo
Markets

Stifel starts IntriCon at buy; PT $35

Stifel initiated coverage of IntriCon (NASDAQ:IIN) with a “buy” rating and $35 price and also added IntriCon to the Stifel Select List. The stock closed at $19.60 on April 16. “In our opinion, IntriCon is one of the...

April 17, 2018
Viveve Medical Logo
Markets

Stifel starts Viveve Medical at buy; PT $6

Stifel launched coverage of Viveve Medical (NASDAQ:VIVE) with a “buy” rating and $6 price target. The stock closed at $3.36 on April 16. Viveve is focused on development and marketing the Viveve system and the Geneveve...

April 16, 2018
Cutera
Markets

Stifel starts Cutera at hold; PT $55

Stifel initiated coverage of Cutera (NASDAQ:CUTR) with a “hold” rating and price target of $55. The stock closed at $54.60 on April 16. Cutera develops and manufactures products used various aesthetic procedures...

April 16, 2018
vTv Therapeutics Logo
Markets

Stifel cuts vTv Therapeutics to hold; PT to $1 from $12

Stifel downgraded vTv Therapeutics (NASDAQ:VTVT) to “hold” from “buy” and slashed its price target to $1 from $12 after the company reported negative top line results from its Phase 3 STEADFAST study in mild Alzheimer’s...

April 10, 2018
Dicerna Logo
Markets

Stifel ups Dicerna Pharma PT to $17 from $10

Stifel raised its price target for Dicerna Pharmaceuticals (NASDAQ:DRNA) to $17 from $10 after the company reported fourth quarter results. The stock closed at $13.50 on March 18. Dicerna is a leading developer of...

March 9, 2018
GlycoMimetics
Markets

Stifel ups GlycoMimetics price target to $23

Stifel raised its price target for GlycoMimetics (NASDAQ:GLYC) to $23 from $17 after the company presented incremental Phase 1/2 data for GMI-1271 in both relapsed/refractory (R/R) and newly-diagnosed AML patients. The...

December 12, 2017